Emerging drugs for chronic constipation

Michael D. Crowell, Lucinda A. Harris, Tisha N. Lunsford, John K. DiBaise

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Chronic constipation (CC) is one of the most common functional gastrointestinal disorders. CC is estimated to affect up to 27% of the North American population. Although not life-threatening, CC can have profoundly negatively affects on quality of life and result in significant economic burden in terms of both direct and indirect healthcare costs. Possible etiologies for CC include alterations in gastrointestinal motility and secretion. Research efforts in CC have begun to identify multifactorial and often overlapping etiologies including abnormalities in myenteric neurons, alterations in neurotransmitters and their receptors, and incoordination of the muscles of the pelvic floor or anorectum. CC may be influenced by genetic predisposition, environmental factors and stress. In this article, the safety and efficacy of traditional and emerging therapies for CC are examined.

Original languageEnglish (US)
Pages (from-to)493-504
Number of pages12
JournalExpert Opinion on Emerging Drugs
Volume14
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Constipation
Pharmaceutical Preparations
Neurotransmitter Receptor
Gastrointestinal Motility
Pelvic Floor
Gastrointestinal Diseases
Ataxia
Genetic Predisposition to Disease
Health Care Costs
Economics
Quality of Life
Safety
Neurons
Muscles
Research
Population

Keywords

  • Chronic constipation
  • Drugs
  • Functional
  • Irritable bowel syndrome
  • Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Crowell, M. D., Harris, L. A., Lunsford, T. N., & DiBaise, J. K. (2009). Emerging drugs for chronic constipation. Expert Opinion on Emerging Drugs, 14(3), 493-504. https://doi.org/10.1517/14728210903146890

Emerging drugs for chronic constipation. / Crowell, Michael D.; Harris, Lucinda A.; Lunsford, Tisha N.; DiBaise, John K.

In: Expert Opinion on Emerging Drugs, Vol. 14, No. 3, 09.2009, p. 493-504.

Research output: Contribution to journalArticle

Crowell, MD, Harris, LA, Lunsford, TN & DiBaise, JK 2009, 'Emerging drugs for chronic constipation', Expert Opinion on Emerging Drugs, vol. 14, no. 3, pp. 493-504. https://doi.org/10.1517/14728210903146890
Crowell MD, Harris LA, Lunsford TN, DiBaise JK. Emerging drugs for chronic constipation. Expert Opinion on Emerging Drugs. 2009 Sep;14(3):493-504. https://doi.org/10.1517/14728210903146890
Crowell, Michael D. ; Harris, Lucinda A. ; Lunsford, Tisha N. ; DiBaise, John K. / Emerging drugs for chronic constipation. In: Expert Opinion on Emerging Drugs. 2009 ; Vol. 14, No. 3. pp. 493-504.
@article{8b03ebf2af574b49af4a7db952ec6a85,
title = "Emerging drugs for chronic constipation",
abstract = "Chronic constipation (CC) is one of the most common functional gastrointestinal disorders. CC is estimated to affect up to 27{\%} of the North American population. Although not life-threatening, CC can have profoundly negatively affects on quality of life and result in significant economic burden in terms of both direct and indirect healthcare costs. Possible etiologies for CC include alterations in gastrointestinal motility and secretion. Research efforts in CC have begun to identify multifactorial and often overlapping etiologies including abnormalities in myenteric neurons, alterations in neurotransmitters and their receptors, and incoordination of the muscles of the pelvic floor or anorectum. CC may be influenced by genetic predisposition, environmental factors and stress. In this article, the safety and efficacy of traditional and emerging therapies for CC are examined.",
keywords = "Chronic constipation, Drugs, Functional, Irritable bowel syndrome, Therapeutics",
author = "Crowell, {Michael D.} and Harris, {Lucinda A.} and Lunsford, {Tisha N.} and DiBaise, {John K.}",
year = "2009",
month = "9",
doi = "10.1517/14728210903146890",
language = "English (US)",
volume = "14",
pages = "493--504",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Emerging drugs for chronic constipation

AU - Crowell, Michael D.

AU - Harris, Lucinda A.

AU - Lunsford, Tisha N.

AU - DiBaise, John K.

PY - 2009/9

Y1 - 2009/9

N2 - Chronic constipation (CC) is one of the most common functional gastrointestinal disorders. CC is estimated to affect up to 27% of the North American population. Although not life-threatening, CC can have profoundly negatively affects on quality of life and result in significant economic burden in terms of both direct and indirect healthcare costs. Possible etiologies for CC include alterations in gastrointestinal motility and secretion. Research efforts in CC have begun to identify multifactorial and often overlapping etiologies including abnormalities in myenteric neurons, alterations in neurotransmitters and their receptors, and incoordination of the muscles of the pelvic floor or anorectum. CC may be influenced by genetic predisposition, environmental factors and stress. In this article, the safety and efficacy of traditional and emerging therapies for CC are examined.

AB - Chronic constipation (CC) is one of the most common functional gastrointestinal disorders. CC is estimated to affect up to 27% of the North American population. Although not life-threatening, CC can have profoundly negatively affects on quality of life and result in significant economic burden in terms of both direct and indirect healthcare costs. Possible etiologies for CC include alterations in gastrointestinal motility and secretion. Research efforts in CC have begun to identify multifactorial and often overlapping etiologies including abnormalities in myenteric neurons, alterations in neurotransmitters and their receptors, and incoordination of the muscles of the pelvic floor or anorectum. CC may be influenced by genetic predisposition, environmental factors and stress. In this article, the safety and efficacy of traditional and emerging therapies for CC are examined.

KW - Chronic constipation

KW - Drugs

KW - Functional

KW - Irritable bowel syndrome

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=69949122920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949122920&partnerID=8YFLogxK

U2 - 10.1517/14728210903146890

DO - 10.1517/14728210903146890

M3 - Article

C2 - 19650747

AN - SCOPUS:69949122920

VL - 14

SP - 493

EP - 504

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 3

ER -